PL
PL · PL · PL-100468788
Breyanzi
ATC L01XL08
Last synced from URPL (Poland) on
Identification
ManufacturerBristol-Myers Squibb Pharma EEIG
CountryPL (PL)
ATC codeL01XL08
Dispensing—
ReimbursedNo
SourceURPL (Poland)
Last synced6/14/2026
Packs · 1
- gtin08027950801787
Annotations
No annotations yet.
Raw payload (JSON)
{
"form": "Dyspersja do infuzji",
"source": "urpl",
"strength": "1,1–70 × 106 komórek/ml / 1,1–70 × 10\n6 komórek/ml",
"packaging": "08027950801787 ¦ Rpz ¦ EU/1/22/1631/001 ¦ 145068\n1 zestaw",
"substance": "lisocabtagenum maraleucelum 1,1–70 × 106 komórek/ml / 1,1–70 × 10\n6 komórek/ml",
"common_name": "Lisocabtagene maraleucel",
"pl_product_id": "100468788",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}Related drugs
Other records sharing ATC code L01XL08.
- ISBreyanziBristol-Myers Squibb Pharma EEIG*
- DKBreyanziBristol-Myers Squibb Pharma EEIG
- NOBreyanziBristol-Myers Squibb Pharma EEIG
- BEBreyanziBristol-Myers Squibb Pharma
- FIBreyanziBristol-Myers Squibb Pharma EEIG
- CABREYANZIBRISTOL-MYERS SQUIBB CANADA
- CZBREYANZIBristol-Myers Squibb Pharma EEIG, Dublin
- NLBreyanzi >= 5.1 x 10^6 cellen [CD4 component], suspensie voor injectieCelgene Europe B.V.
Access this data programmatically
Query Breyanzi and 610,000+ other drug records through a single REST API — with a last_synced_at provenance stamp on every response. Free tier includes 100 requests/day.